147 related articles for article (PubMed ID: 32090453)
1. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
2. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
3. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
6. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
Li B; Zhang J; Yang W; Su L; Yan F
Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
[TBL] [Abstract][Full Text] [Related]
7. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
Yu C; Huang X; Nian H; He P
Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
9. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
10. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
11. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
12. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
13. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
Li B; Su L; Gao J; Jiang L; Yan F
Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy trial design with long-term survivors.
Ding X; Wu J
Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
[TBL] [Abstract][Full Text] [Related]
15. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
16. Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance.
Magirr D; Jiménez JL
Clin Trials; 2022 Apr; 19(2):201-210. PubMed ID: 35257619
[TBL] [Abstract][Full Text] [Related]
17. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
18. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
19. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
Kaneko Y; Morita S
J Biopharm Stat; 2023 Aug; ():1-20. PubMed ID: 37585719
[TBL] [Abstract][Full Text] [Related]
20. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
